Houston has affordablility going for its startups. Photo by Zview/Getty Images

Houston has been long known for its great quality of life and low cost of living, and a new study found that when it comes to startup companies specifically, the greater Houston area has a lot to offer.

Clever, a real estate tool and blog, identified Houston as the sixth best metro in the United States for affordability for startups. The study looked into startup density, investment, the education level of the local population, and the cost of living, and more within the top 50 most populated cities in the U.S.

The resulting ranking had all four of Texas' major metros in the top 10. Austin ranked No. 1 overall, Dallas-Fort Worth ranked at No. 3 (after Atlanta), and San Antonio-New Braunfels came in at No. 8. The study ranked each city based on its density of startups, its growth, investment in business, and its cost of living.

At No. 6 for growth, Houston ranked the highest out of its Texas counterparts, but San Antonio and Houston share the ranking of No. 6 for investment.

"Considering Houston's metro is tied with San Antonio's for the highest average investment in small business, and the proximity to great food, the Gulf of Mexico coast, and attractions like Minute Maid Park and the NASA Space Center, we would definitely suggest considering starting a business here," reads the report.

The Houston area touts a startup density of over 25 percent, which earns it 12th place in that particular category. The report finds that Houston has 6.89 million residents across 8,265.8 square miles and 6.54 percent of Houstonians work at a startup, while 2.8 percent are self employed.

When it comes to GDP and education, Houston has a lot of bragging rights. The Houston area's GDP is reported to be $490 billion, which is the 7th highest in the country, according to the Bureau of Economic Analysis.Meanwhile, almost a quarter of the region's population has a bachelor's degree or higher.

Last month, InnovationMap reported that Inc. 5000 named Houston among its hottest startup cities, citing the three-year revenue growth of Houston's companies that made it on to the Inc. 5000 list. Just before that ranking, Business Facilities magazine named Houston the fourth best startup ecosystem in the U.S., as well as the fourth best city for economic growth potential. Similarly, Commercial Cafe recently named Houston a top large city for early stage startups.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”